For many people, a new year means making resolutions, including losing weight. One in eight adults says they’ve tried a GLP-1 ...

GoodRx, the healthcare company that offers drug coupons for discounts on medications, unveiled that the recently FDA-approved ...

Kalshi is offering NY Post readers a $10 bonus when they open an account and enter the promo code NYPMAX. Upon sign-up, all ...

The digital pharmacy will sell the newly FDA-approved weight-loss pill nationwide, allowing patients to pay through their ...

As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

Dec 23 (Reuters) - Novo Nordisk shares jumped ‌10% on Tuesday after the U.S. Food and ‌Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival Eli ...

FDA approves Novo Nordisk's weight-loss pill Novo aims to regain market share from Eli Lilly Pill broadens potential patient pool The pill is 25 milligrams of semaglutide, the same active ingredient ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

Dec 23 (Reuters) - The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug Wegovy could potentially expand access to millions ...

Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.